Fluoroquinolone toxicity profiles: A review focusing on newer agents

Clinical Infectious Diseases

Volumn 28, Issue 2, 1999, Pages 352-364

  Lipsky, Benjamin A ^a,b,c   Baker, Catherine A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^c VA Puget Sound   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 0033010428     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515104     Document Type: Review

References (118)

1. 1. Takayama S, Hirohashi M, Kato M, Shimada H. Toxicity of quinolone antimicrobial agents. J Tox Environ Health 1995;45:1-45.
2. 2. Sharma AK, Khosla R, Kela AK, Mehta VL. Fluoroquinolones: antimicrobial agents of the 90's. Indian J Pharmacol 1994;26:249-61.
3. 3. Suh B, Lorber B. Quinolones. Med Clin North Am 1995;79:869-94.
4. 4. Domagala JM. Structure-activity and structure-side effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33: 685-706.
5. 5. Finch RG. The withdrawal of temafloxacin: are there implications for other quinolones? Drug Safety 1993;8:9-11.
6. 6. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994;18:946-50.
7. 7. Davey P, McDonald T. Postmarketing surveillance of quinolones, 1990 to 1992. Drugs 1993;45(suppl 3):46-53.
8. 8. Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993;45(suppl 3):59-64.
9. 9. Smith CR. The adverse effects of fluoroquinolones. J Antimicrob Chemother 1987;19:709-12.
10. 10. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990;26(suppl D):31-44.
11. 11. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991;91(suppl 6A):153S-61S.
12. 12. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988;10(suppl 1):S141-6.
13. 13. Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995;49(suppl 2):16-28.
14. 14. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
15. 15. Levofloxacin (Levaquin) package insert. Raritan, New Jersey: Ortho-McNeil Pharmaceutical, 1996.
16. 16. File TM, Segreti J, Dunbar L, et al. A multicenter randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
17. 17. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998;7:101-9.
18. 18. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42(2):206-13.
19. 19. Adelglass J, DeAbate CA, McElvaine P, Fowler CL, LoCocco J, Campbell T. A comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 1998 (in press).
20. 20. Sydnor TA, Kopp EJ, Anthony K, LoCoco J, Kim SS, Fowler CL. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998;80(4):357-62.
21. 21. Nicodemo AC, Robledo JA, Jasovich A, Neto W. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998;52:69-74.
22. 22. Nichols R, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997;90:1193-200.
23. 23. Klimberg IW, Cox CE, Fowler CL, King W, Kim SS, Callery-D'Amico S. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infections. Urology 1998;51:610-5.
24. 24. Richard GA, Childs SJ, Fowler CL, Pittman W, Nicolle LE, Callery-D'Amico S. Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharmacy and Therapeutics 1998;23:534-40.
25. 25. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52(1):51-60.
26. 26. Ofloxacin (Floxin) package insert. Raritan, New Jersey: Ortho-McNeil Pharmaceutical, 1997.
27. 27. Sparfloxacin (Zagam) package insert. Collegeville, Pennsylvania: Rhône-Poulenc Rorer Pharmaceuticals, 1996.
28. 28. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(suppl A):145-60.
29. 29. Lipsky BA, Dorr MB, Magner DJ, Talbot GH. Safety profile of sparfloxacin in North American phase III clinical trials [abstract no LM-57]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
30. 30. Carbon CJ. European clinical experience with sparfloxacin in respiratory tract infection. Presented at a symposium entitled "Sparfloxacin: Empiric Antimicrobial Therapy of Respiratory Tract Infections in the Community Setting," in conjunction with the 19th International Congress on Chemotherapy (Montreal). 17 July 1995.
31. 31. Grepafloxacin (Raxar) package insert. Research Triangle Park, North Carolina: Glaxo Wellcome, 1997.
32. 32. Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997;53:817-24.
33. 33. Grepafloxacin: general safety profile. Product information. Research Triangle Park, North Carolina: Glaxo Wellcome, 1997.
34. 34. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998;42:114-20.
35. 35. Topkis S, Swarz H, Breisch SA, Maroli AN. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Clinical Therapeutics 1997;19:975-88.
36. 36. Trovafloxacin (Trovan) package insert. New York: Pfizer, 1998.
37. 37. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother 1997;39(suppl B):75-80.
38. 38. Goldstein EJ. Possible role of the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis 1996;23(suppl 1): S25-30.
39. 39. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;39(suppl B):1-14.
40. 40. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996;37:955-63.
41. 41. Vincent J, Jeng R, Dogolo LC, Willavize SA, Friedman HL. Effect of trovafloxacin, a new FQ antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997;39(suppl B):81-6.
42. 42. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Safety 1995;13:343-58.
43. 43. Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 1994;3(suppl 3):S168-76.
44. 44. Adam D, von Rosenstiel N. Adverse reactions to quinolones, potential toxicities, drug interactions, and metabolic effects. Infect Dis Clin Pract 1994;3(suppl 3):S177-84.
45. 45. Paton JH, Reeves DS. Adverse reactions to the fluoroquinolones. Adverse Drug Reaction Bulletin 1992;153:575-8.
46. 46. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis 1988;10(suppl 1):S258-61.
47. 47. Geddes AM. Safety of fleroxacin in clinical trials. Am J Med 1993;94(suppl 3A):201S-3S.
48. 48. Donowitz G. Treatment of community-acquired pneumonia with sparfloxacin and cefaclor [abstract no LM10]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
49. 49. Bensch G, Henry D, Stein W, McHugh P, Tipping D, Talbot GH. Treatment of community-acquired pneumonia with sparfloxacin vs. erythromycin [abstract no LM12]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
50. 50. DeAbate CA, Henry D, Bensch G, et al. Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin [abstract no LM9]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
51. 51. Lipsky BA, Miller B, Schwartz R, et al. Treatment of community-acquired complicated skin and skin structure infections with sparfloxacin and ciprofloxacin [abstract no LM11]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
52. 52. Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J 1994;87:869-74.
53. 53. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993;13:461-4.
54. 54. Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987;34(suppl 1):144-9.
55. 55. Altés J, Gascó J, de Antonio J, Salas A, Villalonga C. Ciprofloxacin and delirium [letter]. Ann Intern Med 1989;110:170-1.
56. 56. Reeves RR. Ciprofloxacin-induced psychosis. Ann Pharmacother 1992;26:930-1.
57. 57. Lucet JC, Tilly H, Lerebours G, Gres JJ, Piguet H. Neurological toxicity related to pefloxacin [letter]. J Antimicrob Chemother 1988;21: 811-2.
58. 58. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ofloxacin [abstract no LM7]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
59. 59. Akahane K, Kimura Y, Tsutomi Y, Hayakawa I. Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1994;38:2323-9.
60. 60. Akahane K, Tsutomi Y, Kimura Y, Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemother 1994;40: 412-7.
61. 61. von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs 1994;47:872-901.
62. 62. Levinson JR, Kumar A. Ciprofloxacin-induced cholestatic jaundice: a case report [abstract]. Am J Gastroenterol 1993;88:1619.
63. 63. Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994;28:1162-4.
64. 64. Amitrano L, Gigliotti T, Guardascione MA, Ascione A. Enoxacin acute liver injury. J Hepatol 1992;15:270.
65. 65. López-Navidad A, Domingo P, Cadafalch J, Farrerons J. Norfloxacin-induced hepatotoxicity. J Hepatol 1990;11:277-8.
66. 66. Blum A. Ofloxacin-induced acute severe hepatitis [letter]. South Med J 1991;84:1158.
67. 67. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995;33: 551-71.
68. 68. Mayne JT, Johnson NJ, Kluwe WM, Lencoski DL, Polzer RJ. A study of the phototoxic potential of trovafloxacin in BALB/c mice. J Antimicrob Chemother 1997;39(suppl B):67-73.
69. 69. Lietman PS. Fluoroquinolone toxicities: an update. Drugs 1995;49(suppl 2):159-63.
70. 70. Paton JH, Reeves DS. Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety 1991;6:8-27.
71. 71. Washington Drug Letter. Mouse study irrelevant to Maxaquin, says Searle. Washington, DC: U.S. Government Printing Office, 5 April, 1993:3.
72. 72. Rizk E. The US clinical experience with lomefioxacin, a new once-daily fluoroquinolone. Am J Med 1992;92(suppl 4A):130S-5S.
73. 73. Boccumini LE, Fowler CL, Campbell T, Puertolas L, Kaidbey K. Photoreaction potential of orally administered levofloxacin in healthy subjects [abstract no 291]. Clin Infect Dis 1996;23:913.
74. 74. Owen K. Fluoroquinolone phototoxicity in BALB/c mice: a comparison with grepafloxacin [abstract no 4269]. In: Program and abstracts of the 20th International Congress on Chemotherapy (Sydney, Australia). Stuttgart, Germany: G. Thieme, 1997.
75. 75. Ferguson J. Double blind placebo and ciprofloxacin controlled phototest study of the in vivo phototoxic potential of OPC-17116 in normal volunteers [abstract no M57]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994.
76. 76. Ferguson J, McEwen J, Patterson BE, et al. An open, observer-blind, placebo-controlled, randomized, parallel-group study to investigate the phototoxic potential of trovafloxacin, ciprofloxacin, and lomefloxacin [abstract no A15]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
77. 77. Le Cleach L, Chosidow O, Peytavin G, et al. Blue-black pigmentation of the legs associated with pefloxacin therapy. Arch Dermatol 1995;131:856-7.
78. 78. Drago F, Arditti MR, Rebora A. Henoch-Schönlein purpura induced by fluoroquinolones [letter]. Br J Dermatol 1994;131:448.
79. 79. Remuzon P, Bouzard D, Guiol C, Jacquet J. Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationship of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-y1)naphthyridine analogues of 7-[(1R, 4R)-2,5-diazabicyclo[2.2.1]-heptan-2-y1]-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-oxo-1,8-naphthyridine-3-carboxylix acid. Influence of the configuration on blood pressure in dogs: a quinolone-class effect. J Med Chem 1992;35:2898-909.
80. 80. Pace JL, Gatt P. Fatal vasculitis associated with ofloxacin. Br Med J 1989;299:658.
81. 81. Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemother 1988;34:256-60.
82. 82. Slama TG. Serum sickness-like illness associated with ciprofloxacin. Antimicrob Agents Chemother 1990;34:904-5.
83. 83. Ribard P, Kahn MF. Rheumatological side-effects of quinolones. In: Kahn MF, ed. Baillière's clinical rheumatology: drug-induced rheumatic diseases. London: Baillière Tindall, 1991:175-91.
84. 84. Hayem G, Carbon C. A reappraisal of quinolone tolerability: the experience of their musculoskeletal adverse effects. Drug Safety 1995;13: 338-42.
85. 85. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-204.
86. 86. FDA Medical Bulletin. Washington, DC: U.S. Government Printing Office, 6 August 1995.
87. 87. Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Engl J Med 1994;331:748.
88. 88. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995;332:193.
89. 89. Pierfitte C, Gillet P, Royer RJ. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995;332:193.
90. 90. McGarvey WC, Singh D, Trevino SG. Partial achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot and Ankle International 1996;17:496-8.
91. 91. Meyboom RH, Olsson S, Knol A, Dekens-Konter JA, de Koning GH. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives. Drug Safety 1994;3:185-9.
92. 92. Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997;53:700-25.
93. 93. Thomas SL. Drugs, QT interval abnormalities and ventricular arrythmias. Adverse Drug Interactions and Toxicological Reviews 1994;13:77-102.
94. 94. Jaillon P, Morganroth J, Brumpt I, Talbot G, Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996;37(suppl A):161-7.
95. 95. Lipsky BA. Sparfloxacin: a new fluoroquinolone for community-acquired lower respiratory infections. Pharmacy and Therapeutics 1997;22:187-97.
96. 96. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointe probably related to sparfloxacin [letter]. Eur J Clin Microbiol Infect Dis 1996;15:350-1.
97. 97. Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 1992;30:414-6.
98. 98. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257-67.
99. 99. Camp KA, Miyagi SL, Schroeder DJ. Potential quinolone-induced cartilage toxicity in children. Ann Pharmacother 1994;28:336-8.
100. 100. Chyský V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991;19:289-96.
101. 101. Schaad UB. Use of the quinolones in paediatrics. Drugs 1993;45(suppl 3):37-41.
102. 102. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother 1990;26(suppl F):25-9.
103. 103. Chevalier X, Albengres E, Voisin MC, Tillement JP, Larget-Piet B. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Safety 1992;7:310-4.
104. 104. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy Commission. Pediatr Infect Dis J 1995;14:1-9.
105. 105. Sanders WE Jr. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis 1988;10: 528-43.
106. 106. McDermott JL, Gideonse N, Campbell JW. Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient. J Am Geriatr Soc 1991;39:909-10.
107. 107. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effect on the pharmacokinetics of a single 500 mg oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:1562-5.
108. 108. Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994;38(4):799-804.
109. 109. Wurtz RM, Abrams D, Becker S, Jacobson MA, Mass MM, Marks SH. Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients [letter]. Lancet 1989;1:955-6.
110. 110. Peters B, Pinching AJ. Fatal anaphylaxis associated with ciprofloxacin in a patient with AIDS related complex [letter]. Br Med J 1989;298:605.
111. 111. Berger TG, Franklin N. Anaphylactoid reaction to ciprofloxacin in a patient infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26(Pt 1):256-7.
112. 112. Lucena MI, Marquez M, Velasco JL, Andrade RJ. Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome. Arch Intern Med 1995;155:114-5.
113. 113. Chien SC, Chow AT, Rogge MC, Williams RR, Hendrix W. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997;41:1765-9.
114. 114. Rubinstein E, Potgieter P, Davey P, Norrby SR. The use of fluoroquinolones in neutropenic patients - analysis of adverse effects. J Antimicrob Chemother 1994;34:7-19.
115. 115. Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989;87(suppl 5A):37S-9S.
116. 116. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994;84:535-8.
117. 117. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42:1336-9.
118. 118. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989;33:1778-82.